EASD 24 - We are joined by Dr Helen Coulhoun (University of Edinburgh, UK) to discuss the key findings of a prespecified analysis of the SELECT trial, which investigated the effectiveness of semaglutide in reducing major cardiac events in the presence of impaired kidney function in patients with overweight and obesity.

Findings showed that participants in the study with reduced eGFR and/or albuminuria had a higher rate of MACE in the SELECT trial when compared to patients without these heightened risk factors. However, semaglutide 2.4% was as effective at reducuing MACE in those with higher risk factors as it was in those without. No additional safety concerns were identified in this patient group.

Interview Questions:
1. Could you remind us a bit about the SELECT Trial's design and key outcomes?
2. What was the reasoning behind this prespecified analysis?
3. What were the main findings?
4. What are the implications of these findings on clinical practice?
5. Where are the knowledge gaps, and what further study is needed?

Recorded remotely from Edinburgh, 2024.

Editor: Jordan Rance
Video Specialist: Dan Brent